omalizumab worth it in severe persistent asthma

Inpharma 1562 - 4 Nov 2006 Omalizumab worth it in severe persistent asthma Omalizumab provides cost offsets, improves QOL, and has an "attractive" incremental cost effectiveness ratio (ICER) when compared with standard care among patients with severe persistent allergic asthma in Sweden, according to a multinational group of investigators. To assess the cost effectiveness of adding omalizumab to optimised standard therapy among such patients who remained uncontrolled on GINA * 2002 step 4 therapy, the investigators developed a Markov model using efficacy data obtained from the 28-week INNOVATE trial and Swedish life table and cost data. ** The model had a lifelong time horizon and assumed patients to enter at age 40 years; the treatment effect of omalizumab was modelled constantly for 5 years, after which all patients would revert to standard therapy alone. The base-case analysis showed that the addition of omalizumab would be associated with an additional lifetime cost of €42 754 for a gain of 0.762 quality- adjusted life-years (QALYs) versus standard therapy alone. † This would represent an ICER of €56 091 per QALY gained for omalizumab compared with standard therapy. The accepted cost per QALY gained threshold is €53 384 in Sweden, the investigators note. Sensitivity analyses revealed the model to be most sensitive to changes in asthma fatality rate, patient adherence to treatment, and independence of future asthma exacerbations from previous events. * Global Initiative for Asthma ** The study was supported by a grant from Novartis, with which two of the investigators were affiliated. † Costs were those associated with drug acquisition, physician visits, exacerbations, hospitalisation, and added years of life. Costs and outcomes were discounted at an annual rate of 3%, and were calculated from a societal perspective. Dewilde S, et al. The economic value of anti-IgE in severe persistent, IgE- mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Current Medical Research and Opinion 22: 1765-1776, No. 9, Sep 2006 801050719 1 Inpharma 4 Nov 2006 No. 1562 1173-8324/10/1562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 13-Dec-2016

213 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

Inpharma 1562 - 4 Nov 2006

Omalizumab worth it in severepersistent asthma

Omalizumab provides cost offsets, improves QOL,and has an "attractive" incremental cost effectivenessratio (ICER) when compared with standard care amongpatients with severe persistent allergic asthma inSweden, according to a multinational group ofinvestigators.

To assess the cost effectiveness of addingomalizumab to optimised standard therapy among suchpatients who remained uncontrolled on GINA* 2002step 4 therapy, the investigators developed a Markovmodel using efficacy data obtained from the 28-weekINNOVATE trial and Swedish life table and cost data.**

The model had a lifelong time horizon and assumedpatients to enter at age 40 years; the treatment effect ofomalizumab was modelled constantly for 5 years, afterwhich all patients would revert to standard therapyalone.

The base-case analysis showed that the addition ofomalizumab would be associated with an additionallifetime cost of €42 754 for a gain of 0.762 quality-adjusted life-years (QALYs) versus standard therapyalone.† This would represent an ICER of €56 091 perQALY gained for omalizumab compared with standardtherapy. The accepted cost per QALY gained threshold is€53 384 in Sweden, the investigators note.

Sensitivity analyses revealed the model to be mostsensitive to changes in asthma fatality rate, patientadherence to treatment, and independence of futureasthma exacerbations from previous events.* Global Initiative for Asthma** The study was supported by a grant from Novartis, with which twoof the investigators were affiliated.† Costs were those associated with drug acquisition, physician visits,exacerbations, hospitalisation, and added years of life. Costs andoutcomes were discounted at an annual rate of 3%, and werecalculated from a societal perspective.

Dewilde S, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. CurrentMedical Research and Opinion 22: 1765-1776, No. 9, Sep 2006 801050719

Journal review omalizumab

5.01.513 Xolair® (omalizumab) · Hives are itchy red areas on the skin. They can be small as a pencil ... Severe persistent asthma Adults and adolescents (6 years of age and above)

ICD-10-CM Provider Documentation Highlights€¦ · status asthmaticus) – Moderate persistent asthma (uncomplicated; exacerbation; status asthmaticus) – Severe persistent asthma

38392 omalizumab

ACOS Update - Association of PAs in Allergy Asthma & Immunology · 2019-08-01 · Asthma-COPD overlap syndrome (ACOS) is characterized by persistent airflow limitation with several

Australian Public Assessment Report for Omalizumab (rch) · 2016-06-26 · Xolair is indicated as add -on therapy to improve asthma control in patients with severe allergic asthma

Clinical Characteristics to Differentiate · Asthma-COPD overlap syndrome (ACOS) [a description] Asthma-COPD overlap syndrome (ACOS) is characterized by persistent airflow limitation

Subject: Xolair (Omalizumab)for Allergic Asthma …...• July 2016: FDA Approves Xolair (omalizumab) for allergic asthma in children placing Xolair as the only biologic for children

(Research Use Only) - Eagle Biosciences · Catalog Number: R111 Instructions BioTeZ recoveryELISA Omalizumab IgE ELISA Assay Kit (RIO) Introduction Allergic asthma is a widespread

FDA Advisory Committee May 15, 2003 Genentech Marketing Application STN 103976 / 0 Omalizumab Recombinant human anti-IgE for treatment of asthma Efficacy

DERP VI Surveillance: Biologic Drugs to Treat Asthma and ...€¦ · Adults or children with persistent or chronic asthma Adults with CSU Interventions Active interventions of interest

Factors associated with persistent disease in women with asthma